[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  quantumup [@Quantumup1](/creator/twitter/Quantumup1) on x 3524 followers Created: 2025-07-18 12:42:09 UTC H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG $NBIX ( $LBPH - $HLBBF $HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story. We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients. During the 16-week double-blind period, relutrigine showed a placebo-adjusted monthly motor seizure reduction of XX% during the double-blind period and seizure freedom in over XX% of patients. Additionally, meaningful gains were observed in alertness, communication and seizure severity as noted by both clinicians and caregivers. At XX months, an average of approximately XX% seizure reduction was observed in patients with a mean of XX days without seizures compared to three days in the baseline period. Reiterate Buy rating and $XXX PT." XXXXX engagements  **Related Topics** [$ucbjf](/topic/$ucbjf) [$biib](/topic/$biib) [$aqst](/topic/$aqst) [investment](/topic/investment) [$hlubf](/topic/$hlubf) [$hlbbf](/topic/$hlbbf) [$lbph](/topic/$lbph) [$nbix](/topic/$nbix) [Post Link](https://x.com/Quantumup1/status/1946188742093586828)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
quantumup @Quantumup1 on x 3524 followers
Created: 2025-07-18 12:42:09 UTC
H.C. Wainwright reitd $PRAX Buy-$105 after Praxis announced that FDA had granted Breakthrough Therapy Designation (BTD) for relutrigine, for the treatment of pediatric patients with SCN2A and SCN8A DEEs. $RAPP $XENE $BHVN $DRUG $NBIX ( $LBPH - $HLBBF $HLUBF) H.C. Wainwright said in its note: "While investor attention has largely been on the upcoming readout of vormatrigine's RADIANT study in focal onset seizures, there has been increasing appreciation that relutrigine is deserving of attention. There's a case to be made that relutrigine's commercial potential in DEEs may even exceed vormatrigine's potential in FOS—we make that statement despite being "bulls" on the vormatrigine story.
We believe the efficacy that relutrigine demonstrated in the EMBOLD study was potentially paradigm-shifting in its ability to offer seizure freedom to patients.
During the 16-week double-blind period, relutrigine showed a placebo-adjusted monthly motor seizure reduction of XX% during the double-blind period and seizure freedom in over XX% of patients. Additionally, meaningful gains were observed in alertness, communication and seizure severity as noted by both clinicians and caregivers. At XX months, an average of approximately XX% seizure reduction was observed in patients with a mean of XX days without seizures compared to three days in the baseline period. Reiterate Buy rating and $XXX PT."
XXXXX engagements
Related Topics $ucbjf $biib $aqst investment $hlubf $hlbbf $lbph $nbix